Share
Market Research Report

AVASTIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By IndicationMetastatic colorectal cancer · Non-squamous non-small cell lung cancer · Recurrent glioblastoma · Metastatic renal cell carcinoma · Persistent cervical cancer · Recurrent cervical cancer · Metastatic cervical cancer · Stage III or IV epithelial ovarian cancer · Stage III or IV fallopian tube cancer · Stage III or IV primary peritoneal cancer · Platinum-resistant recurrent epithelial ovarian cancer · Platinum-resistant recurrent fallopian tube cancer · Platinum-resistant recurrent primary peritoneal cancer · Platinum-sensitive recurrent epithelial ovarian cancer · Platinum-sensitive recurrent fallopian tube cancer · Platinum-sensitive recurrent primary peritoneal cancer · and Hepatocellular carcinoma
  • By Dose StrengthVial (100 mg4 mL) and Vial (400 mg16 mL)
  • By Sales ChannelOnline and Offline
  • By GeographyNorth America · Latin America · Europe · Asia Pacific · Middle East & Africa
  • Published In11 Mar 2026
  • Report CodeCMI8108
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  •  Indication Insights (Revenue, USD Mn, 2021 - 2033)

    • Metastatic colorectal cancer
    • Non-squamous non-small cell lung cancer
    • Recurrent glioblastoma
    • Metastatic renal cell carcinoma
    • Persistent cervical cancer
    • Recurrent cervical cancer
    • Metastatic cervical cancer
    • Stage III or IV epithelial ovarian cancer
    • Stage III or IV fallopian tube cancer
    • Stage III or IV primary peritoneal cancer
    • Platinum-resistant recurrent epithelial ovarian cancer
    • Platinum-resistant recurrent fallopian tube cancer
    • Platinum-resistant recurrent primary peritoneal cancer
    • Platinum-sensitive recurrent epithelial ovarian cancer
    • Platinum-sensitive recurrent fallopian tube cancer
    • Platinum-sensitive recurrent primary peritoneal cancer
    • Hepatocellular carcinoma
  •  Dose Strength Insights (Revenue, USD Mn, 2021 - 2033)

    • Vial (100 mg/4 mL)
    • Vial (400 mg/16 mL)
  •  Sales Channel Insights (Revenue, USD Mn, 2021 - 2033)

    • Online
    • Offline
  • Regional Insights (Revenue, USD Mn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa